Given the context of this document it will be no great surprise that GtoPdb is a recommended 'first-stop-shop' for ADEV information gathering. As a relatively small database it nonetheless has a dense content of quantitative target-ligand molecular mechanisms of action (mmoa) content via the expert curation of journal papers (see 'The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY', 2018, PMID 29149325, the release notes, content statistics and Fig ). Entry points for queries have been described in a recent how-to guide (see 'Accessing Expert-Curated Pharmacological Data in the IUPHAR/BPS Guide to PHARMACOLOGY', 2018, PMID 30040201). While name look-up of entries (including disease terms) can be used it is also possible bypass the naming equivocality problem entirely. This is done by sweeping through target sequence similarity space via the GtoPdb protein BLAST interface and ligand similarity space (for small molecules) via the Ligand search tool. With ~ 1700 human targets and ~9000 ligands (including ~7500 small-molecules) extracted from ~ 10,000 papers coverage is extensive (and includes selected probes). It should also be noted that target and ligand entries are linked to selected high-value sources. However, while human drug and clinical candidate coverage is high, not all recent lead compounds can be captured and (with the notable exception of antimalarials) coverage of antinfectives is not within the current funding mandate.